WellmuneKerry is marketing YBG as Wellmune (maybe introduced in 2017?). Offered in 60 countries. Their talking point is immune boosting. Also trying to differentiate in the market with process superiority (quality matters).
Gilles is a follower (and a ditherer).
Ceapro is a small company in a big company game. They need to be faster and nimble, this is supposed to be an advantage of being small. They will not succeed if they FOLLOW the market and because they are so SLOW they will die.
Move faster please. Sign deals and build plants.